Genital Diseases, Female Clinical Trial
Official title:
Use of the LANDA Embryo Freezing Technique to Validate Frozen Embryo Transfer Success Rates
The aim of this study is to track the outcome from the patients who had embryo cryopreservation as part of their Advanced Reproductive Technology (ART) treatment at West Coast Fertility Centers.
Over the past several decades, considerable effort has been expended toward the successful
cryopreservation of various human cells. While attempts at cryopreservation have been
directed at different tissue types, one of the most vigorously pursued targets has been
reproductive tissue. Historically, cryopreservation of human sperm has existed for several
decades. The earliest reports of pregnancies (Trounson et al., 1983) and births (Zeilmaker
et al., 1984) from the cryopreservation of human embryos occurred in the early 1980s.
Presently, the freezing and storage of human embryos following in vitro fertilization (IVF)
is standard practice at most fertility clinics. In 2003, the CDC Assisted Reproductive
Technology success rates report stated that 4,246 live births occurred out of 17,517
non-donor frozen embryo cycles.
Embryo cryopreservation has been a routine component of clinical IVF programs for more than
2 decades but has a relatively poor outcome in terms of post-thaw survival and pregnancy
rates in a majority of IVF programs. Efficient embryo cryopreservation has several
advantages. It helps to reduce costs and increases cumulative pregnancy rates. It can also
help in cases of IVF cycles where embryos are not transferred due to ovarian hyper
stimulation syndrome. It is also useful when technical difficulties are encountered at the
time of an embryo transfer procedure.
One of the major concerns in IVF is high-order multiple pregnancies, which result from the
transfer of multiple embryos in a given cycle. In the last 5 years, improved stimulation
protocols, advances in culture and laboratory systems, and better identification of viable
embryos have enhanced the success rates of IVF. During the same period, some clinics have
started the practice of transferring two embryos to reduce multiple pregnancy rates without
compromising overall pregnancy rates.
Furthermore, in recent years some European countries, particularly the Scandinavian
countries, have taken a lead in performing elective single-embryo transfers and have
achieved acceptable pregnancy rates. This trend is spreading to other countries. This can
result in surplus embryos being available for freezing. With the application of ICSI, even
patients aged 40 years or older may have embryos to freeze.
Review of the current literature reveals modest post-thaw embryo survival, implantation, and
pregnancy rates. Post-thaw survival rates vary from 50% to 80% for different embryo stages.
Implantation and pregnancy rates have varied from 3% to 15% and 15% to 25% respectively,
which is approximately half of the rates achieved for fresh embryo transfers.
To improve the outcome of frozen ET cycles, we modified various steps of our standard
cryopreservation protocol. In a pilot study on arrested and fragmented embryos (grades 3 and
4), we achieved post-thaw survival rates of 92%, having all blastomeres intact. Encouraged
by the post-thaw survival of these embryos; we propose using this modified protocol in our
frozen embryo transfer program.
;
Observational Model: Case-Only
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04566952 -
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT03562897 -
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
|
Phase 2 | |
Completed |
NCT01456962 -
Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract
|
N/A | |
Completed |
NCT01460979 -
Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma
|
Phase 2 | |
Completed |
NCT00050414 -
A Study of Trabectedin in Patients With Advanced Ovarian Cancer
|
Phase 2 | |
Completed |
NCT01526668 -
Follow-up Strategies for Improved Postoperative Recovery After Benign Hysterectomy
|
N/A | |
Recruiting |
NCT04556071 -
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT01462890 -
Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer
|
Phase 3 | |
Completed |
NCT01523652 -
Pharmacokinetic Study on the Administration of Nadroparin Dosing Serum HGF in Gynecological Patients
|
N/A | |
Recruiting |
NCT06134596 -
Correlation of Clitoral Hood and Labia Minora Measurements and Female Genital Self Image Scale (FGSIS) Scores in Women
|
||
Completed |
NCT02747641 -
Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects
|
N/A | |
Completed |
NCT00365716 -
Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)
|
Phase 2 | |
Completed |
NCT03677336 -
Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI
|
Phase 4 | |
Completed |
NCT02698527 -
The Effect of Buffered Lidocaine Versus Nonbuffered Lidocaine on Pain Scores During Infiltration for Vulvar Biopsies
|
N/A | |
Not yet recruiting |
NCT04807166 -
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
|
Phase 2 | |
Completed |
NCT04858919 -
Transrectal and 3D Transabdominal Ultrasound Compared to Vaginoscopy in Diagnosing Virgins With Genital Lesions
|
N/A | |
Completed |
NCT01628432 -
Effect of Salpingectomy During Conservative Hysterectomy
|
N/A | |
Completed |
NCT02642835 -
A Long Term Follow up of Anterior Meshes for Recurrent Prolapse
|
||
Recruiting |
NCT04061967 -
SMS-based Summons in Cervical Screening
|
N/A | |
Completed |
NCT04746053 -
Ovarian Function and Gynecological Profile of Patients Carrying a Pathogenic Variant of the HNF1B Gene (GYN-HNF1)
|
N/A |